Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1476-4598

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors ; volume:17 ; number:1 ; day:23 ; month:8 ; year:2018 ; pages:1-14 ; date:12.2018
Molecular cancer ; 17, Heft 1 (23.8.2018), 1-14, 12.2018

Creator: Yi, Ming

Contributor: Jiao, Dechao
Xu, Hanxiao
Liu, Qian
Zhao, Weiheng
Han, Xinwei
Wu, Kongming
SpringerLink (Online service)

DOI: 10.1186/s12943-018-0864-3

URN: urn:nbn:de:101:1-2018101805332463111319

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Yi, Ming
Jiao, Dechao
Xu, Hanxiao
Liu, Qian
Zhao, Weiheng
Han, Xinwei
Wu, Kongming
SpringerLink (Online service)

Other Objects (12)

World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

PD-L1 degradation pathway and immunotherapy for cancer

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Comparing VIP and PD‐L1 expression as cancer biomarkers

Hochschulschrift

Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)

Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Regulatory mechanisms of PD-1/PD-L1 in cancers

World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

PD-L1 degradation pathway and immunotherapy for cancer

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Comparing VIP and PD‐L1 expression as cancer biomarkers

Hochschulschrift

Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)

Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Regulatory mechanisms of PD-1/PD-L1 in cancers

World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

PD-L1 degradation pathway and immunotherapy for cancer

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Comparing VIP and PD‐L1 expression as cancer biomarkers

Hochschulschrift

Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)

Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Regulatory mechanisms of PD-1/PD-L1 in cancers

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

PD-L1 degradation pathway and immunotherapy for cancer

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Comparing VIP and PD‐L1 expression as cancer biomarkers

Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)

Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Regulatory mechanisms of PD-1/PD-L1 in cancers

World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

PD-L1 degradation pathway and immunotherapy for cancer

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Comparing VIP and PD‐L1 expression as cancer biomarkers

Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)

Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Regulatory mechanisms of PD-1/PD-L1 in cancers

World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

PD-L1 degradation pathway and immunotherapy for cancer

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Comparing VIP and PD‐L1 expression as cancer biomarkers

Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)

Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Regulatory mechanisms of PD-1/PD-L1 in cancers

Related objects

Reset password